Title : Ipratropium bromide versus short acting beta-2 agonists for stable chronic obstructive pulmonary disease.

Pub. Date : 2006 Apr 19

PMID : 16625543






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Combination therapy with ipratropium plus a short-acting beta-2 agonist conferred benefits over a short-acting beta-2 agonist alone in terms of post-bronchodilator lung function. Ipratropium potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens
2 AUTHORS" CONCLUSIONS: The available data from the trials included in this review suggest that the advantage of regular long term use of ipratropium alone or in combination with a short-acting beta-2 agonist or over a beta-2 agonist alone are small, if the aim is to improve lung function, symptoms and exercise tolerance. Ipratropium potassium calcium-activated channel subfamily M regulatory beta subunit 2 Homo sapiens